Kate Therapeutics (KateTx) is a patient-focused biotechnology company developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined muscle and heart diseases. The company is applying novel technology platforms that directly address the key limitations of current gene therapies, including tissue-specific delivery and gene regulation. These breakthroughs have the potential to improve the efficacy and safety of gene therapies and enable the pursuit of a broader set of targets that are otherwise difficult to drug with current technologies.

Biotechnology

Medical Devices

Therapeutics

Kate Therapeutics

Kevin Forrest

Eric Wang

Aislinn Puga

Nathan Jones

Mark Fielden

Sharif Tabebordbar

Christopher Kurtz

The Leadership Team at Kate Therapeutics is responsible for setting the strategic direction and vision of the company, guiding the development of innovative AAV-based gene therapies. This diverse team of experts collaborates to advance research and development, oversee clinical and operational initiatives, and drive business growth, ensuring that KateTx meets its goal of addressing genetically defined muscular and cardiac diseases through cutting-edge therapeutic solutions.

Leadership Team

Research and Development

Clinical Operations

Leadership Team

About

Team members

Other teams at Kate Therapeutics

Research and Development

Clinical Operations